Uniqure (QURE) Downgraded to “Sell” at BidaskClub

BidaskClub cut shares of Uniqure (NASDAQ:QURE) from a hold rating to a sell rating in a research report sent to investors on Wednesday, BidAskClub reports.

Other research analysts have also recently issued reports about the stock. Chardan Capital raised their price objective on shares of Uniqure from $70.00 to $100.00 and gave the stock a buy rating in a research note on Monday, March 4th. Cantor Fitzgerald reissued a buy rating and set a $81.00 price objective on shares of Uniqure in a research note on Thursday, March 7th. HC Wainwright reissued a buy rating on shares of Uniqure in a research note on Tuesday, February 26th. SunTrust Banks raised their price objective on shares of Uniqure to $76.00 and gave the stock a buy rating in a research note on Tuesday, May 7th. Finally, Zacks Investment Research raised shares of Uniqure from a sell rating to a hold rating in a research note on Thursday, January 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company’s stock. Uniqure presently has a consensus rating of Buy and an average price target of $75.82.

Shares of Uniqure stock opened at $59.74 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 9.51 and a quick ratio of 9.51. Uniqure has a 12-month low of $21.98 and a 12-month high of $69.60. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -25.53 and a beta of 0.99.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.03). Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. As a group, sell-side analysts predict that Uniqure will post -3.07 earnings per share for the current year.

In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of Uniqure stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $58.38, for a total value of $467,040.00. Following the completion of the sale, the chief executive officer now directly owns 421,730 shares of the company’s stock, valued at approximately $24,620,597.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christian Klemt sold 1,546 shares of Uniqure stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total transaction of $88,400.28. Following the completion of the sale, the insider now directly owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The disclosure for this sale can be found here. Insiders sold a total of 82,922 shares of company stock valued at $5,223,849 over the last ninety days. 1.56% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Harvest Group Wealth Management LLC purchased a new stake in Uniqure in the 1st quarter worth approximately $26,000. Kore Private Wealth LLC acquired a new position in Uniqure during the 1st quarter valued at about $30,000. Advisor Group Inc. boosted its stake in Uniqure by 5.3% during the 4th quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 502 shares during the period. Pearl River Capital LLC acquired a new position in Uniqure during the 1st quarter valued at about $32,000. Finally, SEI Investments Co acquired a new position in Uniqure during the 1st quarter valued at about $35,000. 61.30% of the stock is owned by hedge funds and other institutional investors.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Read More: Price to Earnings Ratio (PE)

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.